Slide 1: Immuron CEO presentation at Peak Biotech Showcase
Immuron CEO, Steven Lydeamore presentation at Peak Biotech Showcase Melbourne, Australia, August 21 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at Peak Biotech Showcase on Wednesday 21st August 2024 at Work Club
Slide 2: Travelan and IMM-529 background
are orally active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits direc
Slide 3: References and Forward-Looking Statements
References Connor P, Porter CK, Swierczewski B and Riddle MS. Diarrhea during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5): 546-54; 2012. Hutton, M.L., Cunningham, B.A., Mackin, K.E. et al. Bovine antibodies targeting primary and recurrent Clostridium diff
Slide 4: Biotech Showcase - Steven Lydeamore, CEO
NASDAQ: IMRN ASX: IMC For personal use only Biotech Showcase Steven Lydeamore Chief Executive Officer 21 August 2024
Slide 5: Safe Harbor Statement
SAFE HARBOR STATEMENT C e r ta i n state m e n t s m a d e i n t h i s p re s e nta t i o n a re fo r wa rd - l o o k i n g state m e n t s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c tat i o n s , e st i m ate s a n d p ro j e c t i o n s . Wo rd s s u c h a s For personal use onl
Slide 6: Executive summary
Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases For personal use only Company Overview Financial Snapshot Two commercially available
Slide 7: Travelan record sales
Travelan® record sales Global For personal use only + Full Year FY2024 AUD$4.9 million up 174% on (prior comparative period) pcp + June 2024 Quarter AUD$1.3 million up 253% on pcp and 6% on last quarter Australia + Full Year 2024 AUD$3.7 million up 223% on pcp + June 2024 Quarter AUD$1.0 million up
Slide 8: Addressable market & industry overview
Addressable market & industry overview Billion Dollar Market For personal use only Traveller’s diarrhoea treatment market is large and growing at a CAGR of ~7% Industry tailwinds Travel picking up significantly following COVID lockdowns Frequent Symptom 30% - 70% of travelers experience traveller’s
Slide 9: Technology platform
Technology platform Immuron’s proprietary technology platform For personal use only combines the natural human nutrition & health benefits of bovine colostrum with a novel class of specifically targeted oral polyclonal antibodies that offer delivery within the gastrointestinal (“GI”) tract and can b
Slide 10: Travelan | Mechanism of action
Travelan® | Mechanism of action Pre-Clinical Studies For personal use only Broad spectrum antimicrobial Protects against bacterial Binds to surface layer proteins Toxin neutralization and adhesion to host cell intestinal preventing bacterial clearance of targeted gut epithelia colonization and motil
Slide 11: Status of product portfolio and key milestones
Status of product portfolio and key milestones Travelan® Clostridioides difficile Immuron’s Clinical Programs For personal use only MTEC 21-10-013 grant Phase 2 IMM-529 randomized clinical challenge study to Prevention of recurrent CDI infections Compound or examine a dosing regimen for Travelan® Va
Slide 12: World first triple mechanism of action for CDI
WORLD FIRST TRIPLE MECHANISM OF ACTION FOR CDI IMM-529: pre-IND filed with FDA July 2024 Indication / Target IMM-529 will be indicated for the treatment of recurrent C. difficile For personal use only Population infection Product • Novel antibody-containing therapeutic which neutralizes C. difficile
Slide 13: Positive results support Travelan progress to phase 3
Positive results support Travelan® progress to phase 3 For personal use only IMM-124E Phase 2 + Healthy volunteers were recruited and randomized to receive a single daily oral Travelan® topline clinical dose of 1200 mg of Travelan® or placebo. Dosing commenced 2 days prior to trial results demonstra
Slide 14: IMM-124E Phase strategy
IMM-124E Phase 3 strategy Pre 2H 2024 1H 2025 2H 2025 Post For personal use only Phase 1 clinical study Additional topline data FDA meeting – Phase 3 Initiate Phase 3 Trial duration ~ 2 years (Baltimore, 1996) analysis August 2024 clinical protocol End of Phase 3 FDA meeting Phase 2 clinical study C
Slide 15: Scientific references
Scientific references Travelan® (IMM-124E) For personal use only Travelan® has been shown to reduce both the incidence and severity of ETEC- Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: 10.3109/00365521.2011.574726 induced diarrhea in up to 90% of volunteers Clinical Evaluation of
Slide 16: Steven Lydeamore contact information
For personal use only STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172